News Release

Roles of orexin in energy metabolism during sleep in humans

Peer-Reviewed Publication

International Institute for Integrative Sleep Medicine, University of Tsukuba

A hypnotic agent, orexin receptor antagonist, also modulates energy metabolism.

image: 

EEG record during indirect calorimetry using a whole room metabolic chamber.

view more 

Credit: University of Tsukuba

Tsukuba, Japan—Orexin, named after its role in feeding regulation, is a potent endogenous sleep/wake state regulator and is expected to play an essential role in controlling the cross-talk mechanism between sleep/wake and energy metabolism. In 2014, suvorexant, an orexin receptor antagonist, was approved for treating insomnia, allowing for the physiological functions of orexin to be studied in humans. However, the role of orexin system in the regulation of energy metabolism remains unclear in humans. In this randomized, double-blind, placebo-controlled, crossover study, the researchers evaluated the impact of suvorexant (20 mg) on energy metabolism during sleep and the subsequent wake-up period in 14 healthy men. The total sleep time did not change significantly following suvorexant treatment; however, there was an increase in rapid eye movement (REM) sleep and a decrease in non-REM sleep stage 1. Notably, suvorexant promoted fat oxidation during sleep, with the effect persisting up to the first hour after waking up in the morning. In addition, suvorexant decreased protein catabolism, although it did not impact overall energy expenditure during sleep. These results suggest that the orexin system affects fat oxidation and protein catabolism independent of its roles in sleep/wake control, indicating another potential clinical use of orexin receptor antagonists in the long term. The findings of this study shed light on choosing hypnotic agents for patients with insomnia.

###
This research was supported by the World Premier International Research Center Initiative (WPI), AMED under Grant Number JP21zf0127005 and the Japan Society for Promotion of Science KAKENHI (Grant-in-Aid for Early-Career Scientists [JP21K17657]).

 

Original Paper

Title of original paper:
Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans

Journal:
iScience

DOI:
10.1016/j.isci.2024.110212

Correspondence

Professor Emeritus TOKUYAMA, Kumpei 
International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba

Related Link

International Institute for Integrative Sleep Medicine (WPI-IIIS)

About the World Premier International Research Center Initiative (WPI)
The WPI program was launched in 2007 by Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT) to foster globally visible research centers boasting the highest standards and outstanding research environments. Numbering more than a dozen and operating at institutions throughout the country, these centers are given a high degree of autonomy, allowing them to engage in innovative modes of management and research. The program is administered by the Japan Society for the Promotion of Science (JSPS).

See the latest research news from the centers at the WPI News Portal: https://www.eurekalert.org/newsportal/WPI
Main WPI program site:  www.jsps.go.jp/english/e-toplevel

About International Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba
World-class institute for sleep medicine, aiming to solve the mechanism of sleep/wakefulness by conducting basic to translational research
The mission of IIIS is to be a multidisciplinary, international hub for the research to elucidate the function of sleep and the fundamental mechanisms of sleep/wake regulation, to elucidate molecular pathogenesis of sleep disorders and related diseases, to develop preventive measures, diagnostic methods, and treatments for sleep.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.